Ernexa Therapeutics Inc. (NASDAQ:ERNA) Stock Short Interest Report for October

Ernexa Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the target of a significant increase in short interest in October. As of October 30th, there was short interest totaling 33,263 shares, an increase of 67.3% from the October 15th total of 19,877 shares. Based on an average daily volume of 16,424 shares, the short-interest ratio is currently 2.0 days. Approximately 2.0% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of brokerages have weighed in on ERNA. Wall Street Zen downgraded Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.00.

View Our Latest Research Report on Ernexa Therapeutics

Ernexa Therapeutics Price Performance

ERNA stock traded up $0.07 during midday trading on Monday, reaching $1.75. 16,597 shares of the stock were exchanged, compared to its average volume of 625,285. Ernexa Therapeutics has a 52 week low of $1.67 and a 52 week high of $38.02. The company has a fifty day moving average price of $2.75 and a 200 day moving average price of $6.21. The stock has a market capitalization of $2.97 million, a PE ratio of -0.14 and a beta of 2.75.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last posted its earnings results on Friday, November 6th. The company reported ($1.89) EPS for the quarter, beating the consensus estimate of ($3.84) by $1.95. As a group, analysts anticipate that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.

Ernexa Therapeutics Company Profile

(Get Free Report)

Ernexa Therapeutics, formerly known as Eterna Therapeutics, is a biotechnology company focused on developing cell therapies for cancer. Its research centers on engineering cells to deliver therapeutic agents within tumors. The company’s lead program, ERNA-101, is an investigational therapy based on allogeneic mesenchymal stem cells engineered to produce interleukin-12, an immune-signaling protein. The approach is intended to concentrate immune activity in the tumor environment. ERNA-101 remains in development, and Ernexa does not have an approved product.

Further Reading

Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.